Results 281 to 290 of about 779,413 (310)
Bone Turnover Markers, n-Terminal Propeptide of Type I Procollagen and Tartrate-Resistant Acid Phosphatase Type 5b, for Predicting Castration Resistance in Prostate Cancer. [PDF]
Kano H +13 more
europepmc +1 more source
ST6GAL1 plays a critical role in tumor progression and immune regulation in colorectal cancer (CRC). Its depletion significantly suppresses the malignant phenotype of CRC cells and enhances the efficacy of anti‐PD‐L1 therapy. High ST6GAL1 expression promotes an immune‐activated tumor microenvironment (TME), characterized by increased infiltration of ...
Ximo Xu +15 more
wiley +1 more source
Elevated spliced form of X‐box–binding protein 1 (XBP1) correlates with unfavorable responses to endocrine therapy plus CDK4/6 inhibitors in HR+/HER2− advanced breast cancer. XBP1s facilitates cell proliferation and G1/S transition by transcriptionally activating SND1, thereby activating the E2F1 pathway.
Yuting Sang +11 more
wiley +1 more source
Using the convolutional neural network model VDLIN, Co7 is identified as a promising therapeutic candidate. Co7 demonstrates distinct advantages over MCB by effectively balancing anti‐inflammatory and immune‐stimulatory functions, making it a potential novel approach for immune modulation.
Xuefei Guo +6 more
wiley +1 more source
Integrin α8‐Mediated Pericyte Morphogenesis Controls Blood‐Brain Barrier Integrity
This study highlights that ITGA8 impacts pericyte morphology and function, both crucial for BBB integrity, via RhoA/ROCK signaling, thus influencing TGF‐β1 activation through cytoskeletal tension and ECM interactions. Notably, in post‐ischemic recovery models, ITGA8 deficiency exacerbates vascular dysfunction by impairing pericyte‐mediated BBB ...
Chang‐Xiong Gong +16 more
wiley +1 more source
FBXO44 promotes colorectal cancer progression by targeting FOXP1 for ubiquitin‐mediated degradation. This study reveals a phosphorylation‐dependent mechanism involving AURKA and highlights the FBXO44/FOXP1/Cyclin E2 axis as a potential therapeutic target in colorectal cancer.
Hongxu Nie +10 more
wiley +1 more source
Skullcapflavone II (SkII) significantly alters serine metabolism in gastric cancer cells by directly targeting the L‐serine transporter SLC1A4, thereby inhibiting L‐serine uptake rather than de novo synthesis. This disruption of serine metabolism by SkII leads to increased oxidative stress and consequent mitochondrial damage.
Jing Zhao +10 more
wiley +1 more source

